Summit Trail Advisors LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Summit Trail Advisors LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,257 shares of the biopharmaceutical company’s stock after buying an additional 108 shares during the period. Summit Trail Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,321,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. West Paces Advisors Inc. boosted its stake in Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 23 shares during the period. Stephens Consulting LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $26,000. Sachetta LLC grew its position in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares during the last quarter. Crewe Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the 1st quarter valued at $28,000. Finally, Lynx Investment Advisory purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $33,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

REGN has been the subject of several analyst reports. Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Wells Fargo & Company boosted their target price on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Canaccord Genuity Group restated a “buy” rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Truist Financial reiterated a “buy” rating and set a $1,200.00 target price (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 2nd. Finally, TD Cowen increased their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,111.30.

Insiders Place Their Bets

In other news, EVP Marion Mccourt sold 1,137 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the transaction, the executive vice president now directly owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Marion Mccourt sold 1,137 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the sale, the executive vice president now directly owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now directly owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,026 shares of company stock valued at $11,498,705. 7.48% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $1,145.03 on Friday. The stock’s fifty day moving average price is $1,131.75 and its two-hundred day moving average price is $1,032.21. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The firm has a market cap of $126.17 billion, a PE ratio of 33.83, a price-to-earnings-growth ratio of 3.93 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same quarter last year, the company posted $8.79 EPS. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.